X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (54) 54
female (52) 52
oncology (48) 48
breast neoplasms - drug therapy (47) 47
index medicus (46) 46
middle aged (46) 46
adult (41) 41
aged (38) 38
treatment outcome (38) 38
antineoplastic combined chemotherapy protocols - therapeutic use (35) 35
breast cancer (33) 33
breast neoplasms - pathology (32) 32
neoadjuvant therapy (30) 30
chemotherapy (27) 27
chemotherapy, adjuvant (23) 23
trastuzumab (21) 21
cancer (20) 20
neoplasm staging (18) 18
breast neoplasms - surgery (17) 17
disease-free survival (16) 16
survival (16) 16
taxoids - administration & dosage (16) 16
antineoplastic combined chemotherapy protocols - adverse effects (15) 15
breast neoplasms - mortality (15) 15
cyclophosphamide - administration & dosage (15) 15
drug administration schedule (14) 14
prognosis (14) 14
therapy (14) 14
prospective studies (13) 13
antibodies, monoclonal, humanized - administration & dosage (12) 12
adjuvant chemotherapy (11) 11
breast neoplasms - chemistry (11) 11
breast neoplasms - metabolism (11) 11
capecitabine (11) 11
cyclophosphamide (11) 11
receptor, erbb-2 - analysis (11) 11
receptor, erbb-2 - metabolism (11) 11
adjuvant treatment (10) 10
care and treatment (10) 10
docetaxel (10) 10
doxorubicin (10) 10
drug therapy (10) 10
epirubicin - administration & dosage (10) 10
lapatinib (10) 10
neoadjuvant chemotherapy (10) 10
open-label (10) 10
quinazolines - administration & dosage (10) 10
research (10) 10
hematology, oncology and palliative medicine (9) 9
paclitaxel (9) 9
young adult (9) 9
biomarkers, tumor - analysis (8) 8
cancer therapies (8) 8
doxorubicin - administration & dosage (8) 8
health aspects (8) 8
multicenter (8) 8
neoadjuvant therapy - methods (8) 8
paclitaxel - administration & dosage (8) 8
preoperative chemotherapy (8) 8
randomized controlled trials as topic (8) 8
women (8) 8
aged, 80 and over (7) 7
antineoplastic agents - therapeutic use (7) 7
fluorouracil - administration & dosage (7) 7
medicine & public health (7) 7
pathological complete response (7) 7
receptor (7) 7
receptor, erbb-2 - antagonists & inhibitors (7) 7
surgery (7) 7
trial (7) 7
abridged index medicus (6) 6
analysis (6) 6
antibodies, monoclonal, humanized - adverse effects (6) 6
breast neoplasms - genetics (6) 6
clinical trials (6) 6
combination (6) 6
deoxycytidine - administration & dosage (6) 6
deoxycytidine - analogs & derivatives (6) 6
fluorouracil - analogs & derivatives (6) 6
follow-up studies (6) 6
her2 (6) 6
immunohistochemistry (6) 6
plus (6) 6
product development (6) 6
quinazolines - adverse effects (6) 6
quinazolines - therapeutic use (6) 6
time factors (6) 6
antibodies, monoclonal, humanized (5) 5
bevacizumab (5) 5
carcinoma, ductal, breast - drug therapy (5) 5
dose-response relationship, drug (5) 5
efficacy (5) 5
epirubicin (5) 5
further section (5) 5
further section · weitere sektionen (5) 5
germany (5) 5
mastectomy, segmental (5) 5
metastasis (5) 5
oncology, experimental (5) 5
paclitaxel - adverse effects (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9938, pp. 164 - 172
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 7, pp. 747 - 756
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9816, pp. 633 - 640
Summary Background The anti-HER2 monoclonal antibody trastuzumab and the tyrosine kinase inhibitor lapatinib have complementary mechanisms of action and... 
Internal Medicine | ADJUVANT CHEMOTHERAPY | APOPTOSIS | CELLS | WOMEN | MEDICINE, GENERAL & INTERNAL | GW572016 | ERBB2 | INHIBITOR | PLUS | Breast Neoplasms - surgery | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Diarrhea - chemically induced | Breast Neoplasms - chemistry | Antibodies, Monoclonal, Humanized - administration & dosage | Liver - drug effects | Adult | Female | Quinazolines - administration & dosage | Receptor, ErbB-2 - antagonists & inhibitors | Chemotherapy, Adjuvant | Biomarkers, Tumor - antagonists & inhibitors | Paclitaxel - administration & dosage | Antibodies, Monoclonal, Humanized - adverse effects | Drug Administration Schedule | Administration, Oral | Biomarkers, Tumor - analysis | Liver - metabolism | Paclitaxel - adverse effects | Treatment Outcome | Breast Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Neoadjuvant Therapy - methods | Quinazolines - adverse effects | Aged | Infusions, Intravenous | Receptor, ErbB-2 - analysis | Trastuzumab | Drug therapy | Breast cancer | Genetic aspects | Medical research | Ligands | Cytotoxicity | Mammography | Kinases | Cancer therapies | pathology | Liver | methods | Antibodies | Oral | Quinazolines | Breast Neoplasms | Tumor Markers | administration & dosage | Surgery | Paclitaxel | Neoadjuvant Therapy | Adjuvant | Monoclonal | chemistry | Administration | drug therapy | chemically induced | Intravenous | Infusions | Humanized | Antineoplastic Combined Chemotherapy Protocols | Diarrhea | drug effects | Biological | analysis | Kirurgi | antagonists & inhibitors | Chemotherapy | Receptor | adverse effects | metabolism | Cancer and Oncology | therapeutic use | Cancer och onkologi | erbB-2
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 2, pp. 135 - 144
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 7, pp. 631 - 641
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 10, pp. 1137 - 1146
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 3, pp. 345 - 356
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2012, Volume 30, Issue 15, pp. 1796 - 1804
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2012, Volume 366, Issue 4, pp. 299 - 309
Journal Article